IAA26 Antibody

What is IAA26 and what role does it play in plant development and viral pathogenesis?

IAA26, also known as PAP1, is an auxin response regulator protein that belongs to the auxin/indole acetic acid (Aux/IAA) family of transcription repressors. It normally functions in auxin-mediated signaling pathways by regulating the expression of auxin-responsive genes. IAA26 contains nuclear localization signals that direct it to the nucleus, where it interacts with auxin response factors (ARFs) to modulate gene expression.

In the context of viral pathogenesis, IAA26 has been identified as a host factor that interacts with the 126/183-kDa replicase protein of Tobacco mosaic virus (TMV). This interaction disrupts the normal localization of IAA26, preventing its accumulation within the nucleus and altering its regulatory function . Studies have demonstrated a correlation between this interaction and the development of disease symptoms, suggesting that virus-induced disruption of auxin signaling contributes to symptomatology .

Research with transgenic plants expressing a proteolysis-resistant form of IAA26 (IAA26-P108L-GFP) has shown that increased accumulation of this protein results in developmental abnormalities including stunting and leaf epinasty. Interestingly, TMV infection of these plants blocks the nuclear localization of IAA26-P108L-GFP and attenuates these developmental phenotypes . This indicates that TMV-induced disease symptoms may be partially attributed to the viral replicase's ability to disrupt IAA26 localization and function.

What techniques are most effective for detecting IAA26 protein in plant tissues?

Several complementary techniques have proven effective for detecting IAA26 protein in plant tissues, each with specific advantages depending on the research question:

It's worth noting that detection sensitivity varies with tissue age. Western immunoblot analysis using GFP-specific antibodies failed to detect IAA26-GFP in 4-week-old leaf tissues but readily detected it in 10-week-old tissues, despite similar mRNA levels . This suggests post-transcriptional regulation affects IAA26 accumulation across developmental stages.

How does IAA26 expression and localization vary across different developmental stages?

IAA26 expression and protein accumulation show significant variations across different developmental stages, which is critical for designing experiments and interpreting results:

• Tissue age-dependent accumulation: Western immunoblot analysis revealed that IAA26-GFP was undetectable in 4-week-old leaf tissues but readily detected in 10-week-old tissues . This age-dependent accumulation occurred despite similar mRNA levels between young and old tissues, indicating post-transcriptional regulation.

• Auxin-mediated degradation: IAA26, like other Aux/IAA proteins, is subject to auxin-mediated degradation. Treatment of older leaf tissues with 50 μM indole acetic acid (IAA) rapidly reduced detectable accumulation of IAA26-GFP . This suggests that higher endogenous auxin levels in younger tissues might contribute to lower IAA26 protein accumulation.

• Subcellular localization: In non-infected tissues, IAA26 localizes predominantly to the nucleus where it performs its regulatory functions. This localization pattern is consistent across developmental stages when IAA26 is present at detectable levels .

The developmental regulation of IAA26 has important implications for viral pathogenesis. The correlation between higher IAA26 accumulation in older tissues and reduced TMV accumulation suggests that IAA26 may play a role in age-related resistance to viral infection . This raises important considerations for experimental design when studying IAA26-virus interactions across different developmental stages.

What methodological approaches are recommended for studying the interaction between IAA26 and viral replicase proteins?

Several complementary methodological approaches are recommended for comprehensive analysis of IAA26-viral replicase interactions:

• Yeast two-hybrid assays: This system has been successfully employed to demonstrate direct interaction between IAA26 and the helicase domain of the TMV replicase protein . The strength of interaction can be quantified using reporter gene assays. For example, researchers have shown that while tomato LeIAA26 interaction with TMV replicase is weaker than that of Arabidopsis AtIAA26, it still produces significant interaction signals .

• Co-localization studies using fluorescent fusion proteins: Expression of IAA26-GFP fusion proteins in virus-infected tissues allows visualization of altered localization patterns. This approach revealed that IAA26, which normally localizes to the nucleus, colocalizes with the TMV replicase protein in cytoplasmic vesicle-like inclusions during infection .

• Transgenic plants expressing modified IAA26 proteins: Plants expressing proteolysis-resistant forms of IAA26 (e.g., IAA26-P108L-GFP) provide valuable tools for studying the functional consequences of replicase interaction . These plants display abnormal developmental phenotypes that are attenuated upon TMV infection, indicating that the interaction disrupts IAA26 function .

• Mutational analysis of viral replicase: Viral mutants with altered interaction capabilities, such as TMV-V1087I which has reduced interaction with IAA26, can be used to assess the biological significance of this interaction . Comparative analysis of wild-type and mutant virus accumulation in plants with different IAA26 expression levels provides insights into the functional relevance of this interaction.

• Immunoprecipitation followed by mass spectrometry: This approach can identify additional host factors that may form complexes with IAA26 and viral replicase proteins, providing a more comprehensive understanding of the interaction network.

When implementing these approaches, it's important to consider tissue age and developmental stage, as IAA26 accumulation varies significantly between young and old tissues, which may affect interaction dynamics .

How can researchers distinguish between the effects of IAA26 disruption and other viral pathogenicity mechanisms?

Distinguishing between IAA26 disruption and other viral pathogenicity mechanisms requires carefully designed experimental approaches:

By integrating these approaches, researchers can more effectively attribute specific aspects of viral pathogenesis to IAA26 disruption versus other pathogenicity mechanisms.

What are the challenges in developing highly specific antibodies against IAA26 versus other Aux/IAA family members?

Developing highly specific antibodies against IAA26 that don't cross-react with other Aux/IAA family members presents several significant challenges:

• Sequence homology among Aux/IAA proteins: Aux/IAA proteins share significant sequence similarity, particularly in the four conserved domains that characterize this family. For example, IAA26, IAA27, and IAA18 show sequence identities ranging from 50-75% . This high degree of homology increases the likelihood of cross-reactivity.

• Identification of unique epitopes: Generating specific antibodies requires identifying regions unique to IAA26. The variable N-terminal region offers the best potential for specificity, but these regions may have suboptimal immunogenicity or be inaccessible in the native protein conformation.

• Post-translational modifications: Aux/IAA proteins undergo various post-translational modifications, including ubiquitination prior to degradation. Antibodies may detect differently modified forms of IAA26 with varying efficiency, complicating interpretation of results.

• Low abundance in certain tissues: IAA26 accumulates at very low levels in young tissues , making it difficult to purify sufficient native protein for antibody production and validation. Recombinant proteins used for immunization may not fully recapitulate the native folding and modifications.

• Validation challenges: Properly validating antibody specificity requires testing against multiple Aux/IAA proteins, ideally including knockouts of IAA26 and related family members. The functional redundancy among Aux/IAA proteins can complicate the generation of clean knockout lines.

Given these challenges, many researchers have opted to use epitope-tagged versions of IAA26, such as IAA26-GFP fusions, which can be detected with commercially available anti-tag antibodies . This approach circumvents specificity issues but introduces the possibility that the tag affects protein function or localization.

What controls are essential when using antibodies to study IAA26 localization and accumulation?

When using antibodies to study IAA26 localization and accumulation, the following controls are essential for generating reliable and interpretable data:

• Specificity controls:

  • Include samples from knockout/knockdown lines lacking IAA26 expression

  • Test for cross-reactivity with recombinant proteins of closely related Aux/IAA family members

  • For epitope-tagged IAA26, include non-transformed wild-type plants as negative controls

• Positive controls:

  • Include samples with known high IAA26 expression (e.g., older leaf tissues where IAA26 accumulates at higher levels)

  • For developmental studies, include tissues from plants expressing IAA26-P108L, which is resistant to auxin-mediated degradation

• Loading controls:

  • Use antibodies against stable housekeeping proteins (e.g., actin, tubulin) to normalize protein loading

  • Include recombinant IAA26 protein standards at known concentrations for quantitative analysis

• Treatment controls:

  • For viral infection studies, include both mock-inoculated and virus-infected tissues harvested at the same time points

  • For auxin-response studies, include samples treated with auxin transport inhibitors

• Technical controls:

  • Include secondary antibody-only controls to assess background signal

  • For immunofluorescence, include autofluorescence controls and single-channel imaging

• Developmental stage controls:

  • Given the significant variation in IAA26 accumulation between young and old tissues, always compare tissues at the same developmental stage

  • Include both young (4-week-old) and mature (10-week-old) tissues to account for age-dependent differences in IAA26 accumulation

• Antibody validation:

  • Perform peptide competition assays to confirm specificity

  • Verify that the antibody can detect both native and denatured forms of the protein if using for multiple applications

These controls help distinguish genuine IAA26 signals from background, cross-reactivity, or artifacts, ensuring robust and reproducible results across different experimental conditions.

How can researchers optimize Western blot protocols for detecting low abundance IAA26 in young tissues?

Detecting low abundance IAA26 in young tissues presents a significant challenge, as evidenced by the failure of standard Western immunoblot protocols to detect IAA26-GFP in 4-week-old leaf tissues despite successful detection in 10-week-old tissues . The following optimizations can improve sensitivity:

• Sample preparation optimizations:

  • Increase starting material (2-3x more tissue from young plants)

  • Use specialized extraction buffers containing protease inhibitor cocktails that specifically target plant proteases

  • Include deubiquitinating enzyme inhibitors to prevent degradation of ubiquitinated IAA26

  • Perform nuclear fractionation to concentrate IAA26, which primarily localizes to the nucleus in non-infected tissues

• Protein concentration techniques:

  • Use TCA precipitation or methanol/chloroform methods to concentrate proteins

  • Implement immunoprecipitation prior to Western blotting to enrich for IAA26

• Electrophoresis and transfer optimizations:

  • Use gradient gels (4-20%) for better resolution

  • Extend transfer time or use semi-dry transfer systems optimized for proteins in IAA26's molecular weight range

  • Use PVDF membranes with smaller pore sizes (0.2 μm) for improved retention of low abundance proteins

• Detection system enhancements:

  • Implement high-sensitivity chemiluminescence substrates designed for femtogram-level detection

  • Use signal enhancement systems such as biotinylated secondary antibodies with streptavidin-HRP

  • Consider fluorescent secondary antibodies with digital imaging systems for better quantification of low signals

• Antibody incubation optimizations:

  • Extend primary antibody incubation time (overnight at 4°C or longer)

  • Optimize antibody concentration through titration experiments

  • Use signal enhancing polymers that increase the number of HRP molecules per antibody

• Controls and standards:

  • Include dilution series of samples from older tissues where IAA26 is detectable

  • Add recombinant IAA26 standards at known concentrations

• Alternative approaches:

  • Consider using more sensitive techniques such as ELISA or Proximity Ligation Assay (PLA) as alternatives to Western blotting

  • Implement mass spectrometry-based targeted proteomics approaches for very low abundance detection

These optimizations collectively increase the likelihood of detecting the low levels of IAA26 present in young tissues, enabling more comprehensive studies across developmental stages.

What experimental design is recommended for studying the effects of IAA26 disruption on viral pathogenesis?

A comprehensive experimental design for studying the effects of IAA26 disruption on viral pathogenesis should include the following elements:

• Plant material selection:

  • Wild-type plants

  • Transgenic plants expressing IAA26-GFP for visualization of localization

  • Transgenic plants expressing proteolysis-resistant IAA26-P108L-GFP, which display developmental phenotypes that are attenuated by viral infection

  • IAA26 knockout/knockdown lines to assess loss-of-function effects

• Viral variants:

  • Wild-type virus (e.g., TMV)

  • Interaction-deficient viral mutants (e.g., TMV-V1087I) that show reduced ability to interact with IAA26

  • Viral constructs expressing fluorescently-tagged replicase for co-localization studies

• Temporal sampling design:

  • Early infection (2-3 days post-inoculation): focus on initial interaction events

  • Mid-infection (5-7 days post-inoculation): assess impact on viral accumulation

  • Late infection (10-14 days post-inoculation): evaluate symptom development

• Developmental stage comparison:

  • Young tissues (4-6 weeks old) with lower IAA26 accumulation

  • Mature tissues (10-12 weeks old) with higher IAA26 accumulation

• Analytical approaches:

  • Virus accumulation: quantitative Western blotting for viral coat protein

  • Protein-protein interaction: co-immunoprecipitation, proximity ligation assay

  • Protein localization: confocal microscopy with fluorescent fusion proteins

  • Symptom development: quantitative assessment of leaf development, plant height, and morphological alterations

• Experimental layout (Table format):

This experimental design enables researchers to specifically attribute changes in viral pathogenesis to IAA26 disruption by comparing wild-type and interaction-deficient viruses across different plant backgrounds and developmental stages.

How can researchers quantitatively assess changes in IAA26 localization during viral infection?

Quantitative assessment of IAA26 localization changes during viral infection requires rigorous image analysis approaches:

• Image acquisition protocols:

  • Capture multiple Z-stack images using confocal microscopy

  • Maintain consistent laser power, detector gain, and pinhole settings across samples

  • Include both nuclear and cytoplasmic regions in each field of view

  • Use appropriate fluorescent markers for cellular compartments (nuclear markers, viral replicase)

• Nuclear/cytoplasmic ratio analysis:

  • Define nuclear and cytoplasmic regions using appropriate markers

  • Measure fluorescence intensity of IAA26-GFP in each compartment

  • Calculate nuclear/cytoplasmic ratio as a quantitative measure of localization

  • Compare ratios between mock-inoculated and virus-infected cells

• Vesicle formation quantification:

  • Count the number of cytoplasmic vesicle-like structures containing IAA26-GFP

  • Measure vesicle size distribution and total vesicular area

  • Assess co-localization with viral replicase using Pearson's correlation coefficient or Manders' overlap coefficient

• Time-course analysis:

  • Perform sequential imaging at defined time points after infection

  • Plot changes in nuclear/cytoplasmic ratio over time

  • Correlate localization changes with virus accumulation

• Statistical approaches:

  • Analyze data from multiple cells (minimum 30-50 cells per condition)

  • Perform appropriate statistical tests (t-test, ANOVA with post-hoc tests)

  • Present data as box plots or violin plots to show distribution of measurements

• Control-normalized quantification:

  • Express changes relative to mock-infected controls

  • Compare wild-type virus effects to those of interaction-deficient viral mutants

• Multi-parameter analysis:

  • Combine localization data with protein accumulation measurements

  • Correlate localization changes with symptom development

By implementing these quantitative approaches, researchers can move beyond qualitative descriptions of IAA26 relocalization during infection to precise measurements that facilitate statistical comparisons across different experimental conditions.

How should researchers interpret contradictory results between different detection methods for IAA26?

Interpreting contradictory results between different IAA26 detection methods requires careful consideration of each method's limitations and a systematic troubleshooting approach:

• Common sources of contradictions and resolution strategies:

  a) Western blotting vs. fluorescence microscopy:

  • Western blotting measures total protein levels while microscopy reveals localization

  • Discrepancy explanation: IAA26 might relocalize without degradation

  • Resolution: Perform subcellular fractionation before Western blotting

  b) mRNA levels vs. protein accumulation:

  • Research has shown similar IAA26 mRNA levels in young and old tissues despite dramatic differences in protein accumulation

  • Discrepancy explanation: Post-transcriptional regulation (e.g., auxin-mediated degradation)

  • Resolution: Assess protein stability using cycloheximide chase experiments

  c) Native antibody vs. GFP fusion detection:

  • GFP fusion may alter protein stability or localization

  • Discrepancy explanation: Tag interference with protein function

  • Resolution: Compare multiple tag positions (N-terminal vs. C-terminal) and sizes

• Biological factors affecting detection:

  a) Developmental stage effects:

  • IAA26-GFP is undetectable by Western blot in 4-week-old tissue but readily detected in 10-week-old tissue

  • Resolution: Always compare same-age tissues and include age controls

  b) Auxin sensitivity:

  • IAA26 is rapidly degraded upon auxin treatment

  • Resolution: Control for auxin levels or use auxin-resistant variants (e.g., IAA26-P108L)

• Technical validation approach:

  a) Method-specific controls:

  • For each detection method, include appropriate positive and negative controls

  • Compare multiple antibodies targeting different epitopes

  b) Orthogonal validation:

  • Implement a third, independent method to resolve contradictions

  • Consider mass spectrometry-based approaches for definitive protein identification

• Integrated data interpretation framework:

  Detection Method	Strengths	Limitations	Best Used For
  Western blotting	Quantitative, size information	Low sensitivity for young tissues	Protein accumulation studies
  IAA26-GFP fluorescence	Direct visualization, localization data	Potential tag artifacts	Localization studies, live imaging
  RT-PCR/qRT-PCR	Sensitive mRNA detection	Doesn't reflect protein levels	Transcriptional regulation studies
  Immunohistochemistry	Tissue context preservation	Fixation artifacts	Tissue-specific expression patterns

When faced with contradictory results, researchers should systematically evaluate which technique is most appropriate for the specific research question, while acknowledging the limitations of each approach. Multiple complementary methods should be employed whenever possible to build a more complete understanding of IAA26 dynamics.

What statistical approaches are recommended for analyzing the relationship between IAA26 disruption and symptom development?

Analyzing the relationship between IAA26 disruption and symptom development requires robust statistical approaches suitable for complex biological interactions:

• Correlation analysis:

  • Pearson or Spearman correlation between quantitative measures of IAA26 disruption (nuclear/cytoplasmic ratio) and symptom severity

  • Multiple correlation analysis to assess relationships between IAA26 localization, virus accumulation, and symptom measures

  • Time-lagged correlation to detect delayed effects of IAA26 disruption on symptom appearance

• Regression models:

  • Multiple linear regression to identify the contribution of IAA26 disruption to symptom development while controlling for other variables

  • Logistic regression for binary outcomes (e.g., presence/absence of specific symptoms)

  • Mixed-effects models for experiments with repeated measures or nested designs

• Comparative statistical approaches:

  • ANOVA with post-hoc tests to compare symptoms across different plant-virus combinations

  • Two-way ANOVA to assess interaction effects between plant genotype (e.g., wild-type vs. IAA26-P108L) and virus type (e.g., wild-type vs. interaction-deficient mutant)

  • Non-parametric alternatives (Kruskal-Wallis, Mann-Whitney) for data that violate normality assumptions

• Multivariate analysis:

  • Principal Component Analysis (PCA) to reduce dimensionality of multiple symptom measures

  • Cluster analysis to identify patterns in symptom development across experimental conditions

  • Canonical correlation analysis to relate sets of IAA26-related variables to sets of symptom variables

• Causal inference approaches:

  • Mediation analysis to determine if IAA26 disruption mediates the relationship between viral infection and symptom development

  • Structural equation modeling to test hypothesized causal pathways

  • Path analysis to quantify direct and indirect effects of IAA26 disruption

• Time-series analysis:

  • Repeated measures ANOVA for time course experiments

  • Growth curve modeling to analyze symptom progression over time

  • Autoregressive models to account for temporal dependencies in symptom development

• Experimental design considerations:

  • Power analysis to determine appropriate sample sizes

  • Control for confounding variables (e.g., environmental conditions, plant age)

  • Randomization and blinding procedures to minimize bias

A particularly informative approach is comparing symptom severity between plants infected with wild-type virus versus interaction-deficient mutants (e.g., TMV-V1087I). Research has shown that transgenic plants expressing IAA26-P108L-GFP display abnormal developmental phenotypes that are attenuated by wild-type TMV infection but less affected by interaction-deficient mutants . Quantifying these differences through appropriate statistical methods provides strong evidence for the specific role of IAA26 disruption in symptom development.

What emerging technologies might advance our understanding of IAA26 function in plant-virus interactions?

Several emerging technologies hold promise for advancing our understanding of IAA26 function in plant-virus interactions:

• CRISPR/Cas-based technologies:

  • Precise genome editing to create series of IAA26 variants with specific mutations

  • Base editing for introducing specific amino acid changes without double-strand breaks

  • CRISPRi/CRISPRa for temporal control of IAA26 expression levels

  • Prime editing for introducing specific mutations in IAA26 interaction domains

• Advanced imaging technologies:

  • Super-resolution microscopy (e.g., STORM, PALM) to visualize IAA26-viral replicase interactions at nanometer resolution

  • Light sheet microscopy for rapid 3D imaging of IAA26 dynamics during infection

  • FRET/FLIM approaches to directly measure protein-protein interactions in living cells

  • Correlative light and electron microscopy to study IAA26 localization in relation to virus-induced cellular structures

• Protein interaction and modification analysis:

  • Proximity labeling (BioID, TurboID) to identify proteins in close proximity to IAA26 during infection

  • Chemical crosslinking mass spectrometry to map interaction interfaces between IAA26 and viral replicase

  • Ubiquitin remnant profiling to identify ubiquitination sites on IAA26 that regulate its stability

  • Phosphoproteomics to identify infection-induced changes in IAA26 phosphorylation

• Single-cell approaches:

  • Single-cell transcriptomics to analyze cell-specific responses to IAA26 disruption

  • Single-cell proteomics to measure IAA26 levels in individual cells during infection

  • Live-cell tracking of IAA26 dynamics in individual cells over the course of infection

• Structural biology approaches:

  • Cryo-electron microscopy to determine the structure of IAA26-viral replicase complexes

  • Hydrogen-deuterium exchange mass spectrometry to map conformational changes upon interaction

  • In-cell NMR to study IAA26 structure and interactions in living cells

• Systems biology integration:

  • Multi-omics integration (transcriptomics, proteomics, metabolomics) to build comprehensive models of IAA26-mediated responses

  • Network analysis to position IAA26 within the broader auxin signaling network during infection

  • Mathematical modeling to predict the impact of IAA26 disruption on auxin-responsive gene expression

These technologies, especially when used in combination, have the potential to provide unprecedented insights into the molecular mechanisms by which viral replicase proteins disrupt IAA26 function and how this disruption contributes to disease symptom development.

How might understanding IAA26-virus interactions inform broader plant disease resistance strategies?

Understanding IAA26-virus interactions could inform novel plant disease resistance strategies through several promising approaches:

• Engineering IAA26 variants resistant to viral manipulation:

  • Identify critical residues in IAA26 required for interaction with viral replicase

  • Develop modified IAA26 proteins that maintain normal function but resist viral interaction

  • Create transgenic plants expressing these interaction-resistant IAA26 variants

• Exploiting virus-induced developmental phenotype attenuation:

  • Research shows that TMV infection attenuates the abnormal developmental phenotype in IAA26-P108L-GFP plants

  • This suggests that controlled modulation of auxin signaling might reduce symptom severity

  • Develop auxin analogs or biosynthesis inhibitors that specifically counteract virus-induced disruptions

• Leveraging developmental stage resistance:

  • IAA26 accumulates at higher levels in mature tissues, correlating with reduced TMV accumulation

  • Understand the molecular basis of this age-related resistance

  • Develop strategies to induce "mature tissue" hormone profiles in younger tissues

• Cross-protection approaches:

  • Develop attenuated viruses with modified replicase proteins that compete with wild-type virus for IAA26 interaction without disrupting its function

  • These modified viruses could potentially protect plants from more virulent strains

• Broad-spectrum resistance through conserved interaction mechanisms:

  • IAA26 interactions are conserved across plant species (Arabidopsis, tomato) and potentially across multiple viruses

  • Target conserved viral features required for these interactions

  • Develop resistance strategies effective against multiple viral pathogens

• Diagnostic applications:

  • Develop biosensors based on IAA26-GFP localization changes to detect early viral infection

  • Create high-throughput screening systems to identify compounds that prevent IAA26-viral replicase interactions

• Predictive tools for symptom severity:

  • Develop models based on virus genotype and plant IAA26 variants to predict symptom severity

  • Enable pre-emptive interventions based on predicted disease impact

The interaction between viral replicase proteins and auxin signaling components represents a conserved pathogenicity mechanism that, once fully understood, could be targeted to develop novel, broadly effective strategies for mitigating viral disease impacts across multiple crop species.